Data from Pharmawand - Curated by EPG Health - Date added 31 May 2019

The 2019 annual meeting will take place from May 31st to June 4th in Chicago, Illinois, USA.

The American Society of Clinical Oncology annual meeting presents the latest research in cancer treatment and care, new therapies and ongoing controversies.

Planned sessions include:

  • Clinical science symposia: EGFR and ROS1: Targeting Resistance (lung cancer), Next-Generation Therapeutics and Biomarkers in Melanoma (skin cancers), Targeting Breast Cancer: Breaking the Code (Women’s health), Geriatric Oncology: Innovative approaches Leading to Improved Outcomes
  • Education sessions: Clinical Controversies in Relapsed Hodgkin Lymphoma: Keeping Pace with Novel Agents and New Options for Salvage Therapy, Local-Regionally Advanced Non–Small Cell Lung Cancer: Advances in Multimodality Treatment
  • Interactive case-based sessions - Multidisciplinary Care in Challenging Sarcoma Scenarios, The Development of a Molecular Tumor Board for Gynecologic Oncology

Further details on the ASCO 2019 annual meeting can be found here.

Find further information in our sponsored learning zones:

Metastatic melanoma – including epidemiology and treatment details for targeted and combination targeted therapies, immunotherapy and chemotherapy.

Chronic lymphocytic leukaemia – featuring key publications and an EACCME accredited CME – ‘Personalisation of chronic lymphocytic leukaemia (CLL) care’.


You will need to login, to leave a comment. is not monitored for collection of adverse event reports. Any adverse events should be reported to your national reporting agency and/or the manufacturer.

Learning Zones

An Learning Zone (LZ) is an area of the site dedicated to providing detailed self-directed medical education about a disease, condition or procedure.

Chronic Lymphocytic Leukaemia (CLL)

Chronic Lymphocytic Leukaemia (CLL)

Refine your knowledge of chronic lymphocytic leukaemia (CLL) with information on pathophysiology, diagnosis, treatment options and more

+ 1 more

Biosimilars Knowledge Centre

Biosimilars Knowledge Centre

What are biologics and how do they differ from small molecule medicines? Discover more about their development, as well as the manufacturing and regulatory processes in the Biosimilars in Oncology Knowledge Centre.

CDK 4/6 inhibitors in metastatic breast cancer

CDK 4/6 inhibitors in metastatic breast cancer

The CDK 4/6 Inhibitors in Metastatic Breast Cancer Learning Zone provides insights and information for metastatic breast cancer (mBC) and CDK 4/6 signalling. This includes the burden and pathophysiology of the disease, the role of CDK 4/6 in cell proliferation and an overview of the CDK 4/6 inhibitors that have been approved for the management of mBC.

Load more

Related Content